• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Nature. Author manuscript; available in PMC Dec 22, 2010.
Published in final edited form as:
PMCID: PMC3008159
NIHMSID: NIHMS231147

Foxp3 occupancy and regulation of key target genes during T-cell stimulation

Abstract

Foxp3+CD4+CD25+ regulatory T (Treg) cells are essential for the prevention of autoimmunity1,2. Treg cells have an attenuated cytokine response to T-cell receptor stimulation, and can suppress the proliferation and effector function of neighbouring T cells3,4. The forkhead transcription factor Foxp3 (forkhead box P3) is selectively expressed in Treg cells, is required for Treg development and function, and is sufficient to induce a Treg phenotype in conventional CD4+CD25 T cells58. Mutations in Foxp3 cause severe, multi-organ autoimmunity in both human and mouse911. FOXP3 can cooperate in a DNA-binding complex with NFAT (nuclear factor of activated T cells) to regulate the transcription of several known target genes12. However, the global set of genes regulated directly by Foxp3 is not known and consequently, how this transcription factor controls the gene expression programme for Treg function is not understood. Here we identify Foxp3 target genes and report that many of these are key modulators of T-cell activation and function. Remarkably, the predominant, although not exclusive, effect of Foxp3 occupancy is to suppress the activation of target genes on T-cell stimulation. Foxp3 suppression of its targets appears to be crucial for the normal function of Treg cells, because overactive variants of some target genes are known to be associated with autoimmune disease.

We developed a strategy to identify genes whose promoters are bound by Foxp3 and whose expression is dependent on that transcription factor (Fig. 1). To generate two cell lines that are genetically matched except for Foxp3, we transduced a Foxp3CD4+ murine T-cell hybridoma with FLAG-tagged Foxp3. This approach was favoured over comparison of ex vivo cells, which are heterogeneous with regard to activation status. The lines provided sufficient numbers of homogeneous cells with appropriate controls to facilitate both location analysis and expression analysis. FACS (fluorescence-activated cell sorting) analysis confirmed that Foxp3 is expressed in the hybridoma at levels comparable to those in ex vivo CD4+CD25+ Treg cells (Supplementary Fig. S1). Previous work has shown that conventional CD4+ T cells ectopically expressing Foxp3 do not upregulate interleukin 2 (Il2) secretion following T-cell receptor (TCR) dependent stimulation13. To confirm that the Foxp3+ hybridomas contain functional Foxp3, we assayed Foxp3 and Foxp3+ cells for Il2 secretion. Indeed, FACS analysis revealed that Il2 secretion is strongly inhibited in phorbol myristate acetate (PMA)/ionomycin stimulated Foxp3+ hybridomas compared to stimulated Foxp3 hybridomas (Supplementary Fig. S2).

Figure 1
Strategy to identify direct Foxp3 transcriptional effects

To identify direct targets of Foxp3, DNA sequences occupied by the transcription factor were identified in a replicate set of experiments using chromatin-immunoprecipitation (ChIP) combined with DNA microarrays. For this purpose, DNA microarrays were used that contain 60-mer oligonucleotide probes covering the region from −8 kilobases (kb) to +2 kb relative to the transcript start sites for approximately 16,000 annotated mouse genes14. The sites occupied by Foxp3 were identified as peaks of ChIP-enriched DNA that span closely neighbouring probes (Fig. 2). Foxp3 was found to occupy the promoters of 1,119 genes in PMA/ionomycin stimulated hybridomas (Supplementary Tables S1 and S2). The well-characterized Foxp3 target gene12,15, Il2, was among the genes occupied by Foxp3 (Fig. 2a). Most of the promoters occupied by Foxp3 in stimulated T cells were also occupied in unstimulated cells (Supplementary Tables S1 and S2, and Supplementary Fig. S3). However, at some promoters Foxp3 binding increased considerably in cells stimulated with PMA/ionomycin (Fig. 2a and Supplementary Fig. S3). Control immunoprecipitation experiments in Foxp3 cells, which produced few positive signals, confirmed the specificity of these results (Supplementary Fig. S4). Our confidence in the binding data was further strengthened by the discovery of a DNA sequence motif, which matches the consensus forkhead motif, at the genomic loci that were bound by Foxp3 (Fig. 2b and Supplementary Table S5). This motif distinguishes Foxp3 bound regions from unbound regions tiled on the promoter arrays with a high level of confidence (P < 10−41). Instances of this motif are significantly more likely to be conserved in Foxp3 bound regions than in promoter regions that are not bound by Foxp3 (P < 10−23), suggesting that these sites serve a functional role (Supplementary Table S5).

Figure 2
Direct Foxp3 targets include key modulators of T-cell function

To gain insights into the cellular functions that are directly regulated by Foxp3 transcriptional control, we compared the list of genes occupied by Foxp3 in stimulated hybridomas to the biological pathways annotated by the Kyoto Encyclopedia of Genes and Genomes (KEGG)16. Among these pathways, Foxp3 target genes are most strongly associated with the TCR signalling pathway (P =1.4 ×10−5) (Fig. 2c). Foxp3 target genes encode proteins that participate at multiple levels of this pathway, including cell surface molecules, signalling components and transcriptional regulators. Many genes with known roles in T cells are missed with existing automated surveys, so we also manually inspected the list of Foxp3 target genes. This revealed that many additional Foxp3 targets are probably important for T-cell function, including microRNAs that are differentially expressed between Treg cells and conventional T cells17 (Fig. 2a and Supplementary Table S3). Surprisingly, Ctla4 was not among the Foxp3 targets, but analysis by RT–PCR (polymerase chain reaction with reverse transcription) revealed no Ctla4 expression in Foxp3 and Foxp3+ hybridomas (data not shown). However, the Foxp3 targets included genes previously reported to be upregulated in Treg cells, such as Il2ra (CD25) (ref. 1), Tnfrsf18 (GITR) (ref. 18), Nrp1 (ref. 19) and Ccr4 (ref. 20), consistent with predictions that these are directly regulated by Foxp3.

Previous reports have shown that only a portion of transcription factor binding events is associated with transcriptional regulation21. To identify the set of genes whose expression is dependent on Foxp3, we performed gene expression profiling on Foxp3 and Foxp3+ T-cell hybridoma cells before and after PMA/ionomycin stimulation. Comparison of data from unstimulated Foxp3 and Foxp3+ cells revealed few differentially expressed genes, suggesting that the transcription factor had little influence on global gene expression in unstimulated hybridomas (Supplementary Table S8). In contrast, PMA/ionomycin-stimulated Foxp3 and Foxp3+ cells showed significant differences in expression of almost 1% of mouse genes. Many of these genes were directly occupied by Foxp3, and Foxp3 binding was predominantly, but not exclusively, associated with genes whose expression is downregulated in stimulated Foxp3+ hybridomas. Foxp3 occupied the promoters of approximately half of the genes in this cluster (Fig. 3a). This set of downregulated target genes is enriched for genes that are implicated in TCR signalling (P = 6.1 × 10−3). Underscoring the significance of this finding, E2f4, an unrelated control transcription factor that occupies ~800 genes in these hybridomas, was found to occupy only one of these promoters (Supplementary Table S4).

Figure 3
Foxp3 directly suppresses the activation of target genes

Only a subset of all Foxp3 occupied genes was found to be differentially expressed. One reason for this could be that Foxp3 requires cofactors to modulate transcription. Recently, FOXP3 was shown to cooperate with NFAT in a DNA-binding complex to activate or repress target gene expression12. Consistent with this report, Foxp3 exerts a more pronounced transcriptional effect in stimulated hybridoma cells than in non-stimulated cells. Importantly, in our experiments, the set of Foxp3 bound genes are enriched (P < 10−19) for the presence of an Nfat DNA sequence motif neighbouring the sites of Foxp3 occupancy (Supplementary Table S5).

We next examined whether the genes regulated by Foxp3 in the T-cell hybridomas show similar regulatory behaviour in ex vivo T cells. Hybridoma cells were used initially because they afforded cells that differ only by Foxp3 status, they provided a homogenous population of non-stimulated T cells, and we could have confidence in genome-wide location data using FLAG-tagged Foxp3. Nonetheless, microarray expression profiling was performed on ex vivo T cells from different mice that express a transgenic TCR alone or together with the TCR agonist ligand22, from which relatively pure populations of naïve CD4+CD25 T helper and Foxp3+CD4+CD25+ Treg cells, respectively, could be isolated. This analysis revealed that many, although not all, of the regulated targets that were identified in the hybridomas show consistent expression patterns in stimulated ex vivo cells (Fig. 3b and Supplementary Fig. S5). Some differences in gene expression, especially genes that are activated by Foxp3 only in Treg cells, may be due to the fact that ex vivo Treg cells are generated through antigenic stimulation23,24 and hence could contain transcriptional cofactors that differ from those in hybridoma cells.

Our findings were further validated for a panel of nine Foxp3 targets. Site-specific primers were used to confirm the binding of Foxp3 to the promoters of these genes (Fig. 3c) and quantitative RT–PCR was used to assay messenger RNA levels in non-stimulated and stimulated hybridomas and ex vivo cells, in the presence and absence of 2 μM cyclosporin A (Fig. 3d). These experiments confirmed the direct effects of Foxp3 at targets that were identified in the genome scale experiments. Notably, in these experiments (Fig. 3d) all genes that were activated following stimulation in Foxp3 cells and repressed in Foxp3+ cells were activated in a calcineurin dependent manner, consistent with the notion that Nfat is involved in their activation. Finally, just as Foxp3 regulates the protein levels of secreted Il2 (Supplementary Fig. S2), cell surface staining and FACS analysis show that Foxp3 regulates the level of Ly6a protein, demonstrating that Foxp3 transcriptional regulation of its targets modulates protein levels (Supplementary Fig. S6).

Taken together, the results from ex vivo T cells and the hybridoma system identify a core set of Foxp3 regulatory targets (Fig. 4a), most of which showed suppressed activation in stimulated Foxp3+ cells. A smaller number of Foxp3 target genes was upregulated in stimulated Foxp3+ cells, including some encoding cell surface molecules with known roles in immunoregulation, such as Ly6a (ref. 25) and Tnfrsf9 (4-1BB) (ref. 26). The results from the hybridoma system indicate that Foxp3 occupies regions of most of its target promoters in both unstimulated and stimulated conditions, but increased binding at some promoters and regulation of most targets is observed after stimulation. Furthermore, in hybridomas the major function of Foxp3 at these genes is to suppress the level of gene activation that would occur if this transcription factor were not expressed (Fig. 4b). Conceivably, the Foxp3 dependent downregulation of T-cell activation and cytokine genes, and upregulation of immunosuppressive cell surface molecules, contribute to both the hyporesponsive and suppressive Treg phenotype.

Figure 4
Core direct regulatory effects of Foxp3

Mutations in some Foxp3 target genes are already known to be associated with autoimmune disease. The protein tyrosine phophatase Ptpn22 is a notable example. In our experiments, Ptpn22 is one of the highest confidence direct targets of Foxp3, it is upregulated on stimulation in Foxp3 cells, and this upregulation is inhibited in Foxp3+ hybridomas (Fig. 3a) and ex vivo Treg cells (Fig. 3b, d). Ptpn22 modulates the signal cascade downstream of the TCR, and mutations in the human PTPN22 have been associated with type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus and Graves' disease, as well as other autoimmune diseases2729. A recent report suggests that one PTPN22 single-nucleotide polymorphism associated with autoimmunity is a gain-of-function mutation30. Our findings are compatible with the hypothesis that the gain-of-function mutation might be pathogenic if mutant PTPN22 is overactive in Treg cells30.

In summary, our data indicate that Foxp3 binds to the promoters of well-characterized regulators of T-cell activation and function. In the T-cell hybridomas studied here, the major role of this transcription factor is to dampen the induction of key genes when Treg cells are stimulated. In ex vivo Treg cells, Foxp3 could also activate the expression of a greater number of genes, perhaps owing to the greater abundance of certain transcriptional cofactors in these cells. Some of the identified Foxp3 target genes have been previously implicated in autoimmune diseases, implying that a therapeutic strategy to recapitulate the function of this transcription factor may have clinical utility for these diseases.

Methods

A detailed description of all materials and methods used can be found in Supplementary Information.

Growth of murine CD4+ T-cell hybridomas and ex vivo T cells

CD4+ 5B6-2 hybridoma cells expressing a PLP139-151-specific TCR, which was kindly provided by V. Kuchroo, were cultured in Dulbecco's modified Eagle medium (Invitrogen). Primary murine CD4+ T cells were cultured in RPMI-1640 medium (Invitrogen). For gene expression profiling, real-time RT–PCR, and location analysis, cells were cultured in the absence or presence of 50 ng ml−1 phorbol 12-myristate 13-acetate (PMA) and 200 ng ml−1 ionomycin at 37°C and harvested after 6 h. Where indicated, cells were preincubated for 1 h with 2 μM cyclosporin A. Details of cell generation and isolation are provided in Supplementary Information.

Antibodies and ChIP assays

Detailed descriptions of antibodies, antibody specificity and ChIP methods used in this study are provided in Supplementary Information.

Promoter array design and data extraction

The design of the oligonucleotide-based promoter array set and data extraction methods are described in Supplementary Information. The microarrays used for location analysis in this study were manufactured by Agilent Technologies (http://www.agilent.com).

Motif analysis

Discovery of the Foxp3 sequence motif from the ChIP-chip binding data was performed using the THEME algorithm. The Foxp3 motif learned by THEME and the Nfat motif from the TRANSFAC database (version 8.3) were used to scan all arrayed sequences to identify matches to the motifs.

Functional classification of bound genes

Comparison of Foxp3 target genes to annotated KEGG biological pathways was performed using the online DAVID tool (http://niaid.abcc.ncifcrf.gov/).

Gene expression profiling

For each hybridoma culture condition, total RNA was prepared from 1 ×107 cells using Trizol (Gibco) followed by additional purification using the RNeasy Mini Kit (Qiagen). Biotinylated antisense cRNA was then prepared according to the Affymetrix standard labelling protocol (one amplification round). For each primary T-cell culture condition, total RNA was isolated from 5 × 105 cells with RNeasy. Biotinylated antisense cRNA was prepared by two rounds of in vitro amplification using the BioArray RNA Amplification and Labelling System (Enzo Life Sciences) according to the protocol for 10–1,000 ng of input RNA provided by the manufacturer. Biotinylated cRNAs of hybridomas and primary T cells were fragmented and hybridized to Affymetrix GeneChip Mouse Expression Set 430 2.0 arrays at the Microarray Core Facility (Dana-Farber Cancer Institute).

Quantitative RT–PCR

To determine transcript levels in T-cell hybridomas and ex vivo T cells, RNA was isolated, reverse-transcribed and subjected to real-time PCR performed on an ABI PRISM thermal cycler using SYBR Green PCR core reagents (Applied Biosystems). Detailed information is provided in Supplementary Information.

Supplementary Material

Supplementary Methods Figures

Supplementary Table 1

Supplementary Table 2

Supplementary Table 3

Supplementary Table 4

Supplementary Table 5

Supplementary Table 6

Supplementary Table 7

Supplementary Table 8

Supplementary Table 9

Supplementary Table 10

Supplementary Table 11

Acknowledgments

We thank members of the Young, von Boehmer and Fraenkel laboratories, as well as R. Jaenisch and D. K. Gifford, for discussions and critical review of the manuscript, especially T. I. Lee, J. Zeitlinger and D. T. Odom. We also thank Biology and Research Computing (BaRC), especially T. Dicesare for graphic assistance, as well as E. Herbolsheimer for computational and technical support. K.K. was supported in part by a fellowship grant from the German Research Foundation. This work was supported in part by a donation from E. Radutzky, and by the Whitaker Foundation (E.F.) and the NIH (H.v.B. and R.A.Y.).

Footnotes

Supplementary Information is linked to the online version of the paper at www.nature.com/nature.

Author Contributions R.A.Y. and H.v.B. contributed both as senior and corresponding authors.

All microarray data from this study are available from ArrayExpress at the EBI (http://www.ebi.ac.uk/arrayexpress) under accession code E-TABM-154.

Reprints and permissions information is available at www.nature.com/reprints.

The authors declare competing financial interests: details accompany the full-text HTML version of the paper at www.nature.com/nature.

References

1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151–1164. [PubMed]
2. Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev. 2006;212:203–216. [PubMed]
3. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nature Rev Immunol. 2002;2:389–400. [PubMed]
4. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nature Immunol. 2005;6:338–344. [PubMed]
5. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–1061. [PubMed]
6. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature Immunol. 2003;4:330–336. [PubMed]
7. Khattri R, et al. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nature Immunol. 2003;4:337–342. [PubMed]
8. Fontenot JD, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22:329–341. [PubMed]
9. Brunkow ME, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nature Genet. 2001;27:68–73. [PubMed]
10. Bennett CL, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature Genet. 2001;27:20–21. [PubMed]
11. Wildin RS, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nature Genet. 2001;27:18–20. [PubMed]
12. Wu Y, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell. 2006;126:375–387. [PubMed]
13. Schubert LA, Jeffery E, Zhang Y, Ramsdell F, Ziegler SF. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem. 2001;276:37672–37679. [PubMed]
14. Boyer LA, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006;441:349–353. [PubMed]
15. Chen C, Rowell EA, Thomas RM, Hancock WW, Wells AD. Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J Biol Chem. 2006;281:36828–36834. [PubMed]
16. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27–30. [PMC free article] [PubMed]
17. Cobb BS, et al. A role for Dicer in immune regulation. J Exp Med. 2006;203:2519–2527. [PMC free article] [PubMed]
18. McHugh RS, et al. CD4+CD25+ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002;16:311–323. [PubMed]
19. Bruder D, et al. Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol. 2004;34:623–630. [PubMed]
20. Iellem A, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4+CD25+ regulatory T cells. J Exp Med. 2001;194:847–853. [PMC free article] [PubMed]
21. Harbison CT, et al. Transcriptional regulatory code of a eukaryotic genome. Nature. 2004;431:99–104. [PMC free article] [PubMed]
22. Klein L, Khazaie K, von Boehmer H. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci USA. 2003;100:8886–8892. [PMC free article] [PubMed]
23. Jordan MS, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nature Immunol. 2001;2:301–306. [PubMed]
24. Kretschmer K, et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nature Immunol. 2005;6:1219–1227. [PubMed]
25. Stanford WL, et al. Altered proliferative response by T lymphocytes of Ly-6A (Sca-1) null mice. J Exp Med. 1997;186:705–717. [PMC free article] [PubMed]
26. Myers LM, Vella AT. Interfacing T-cell effector and regulatory function through CD137 (4–1BB) co-stimulation. Trends Immunol. 2005;26:440–446. [PubMed]
27. Bottini N, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nature Genet. 2004;36:337–338. [PubMed]
28. Wu J, et al. Identification of substrates of human protein-tyrosine phosphatase PTPN22. J Biol Chem. 2006;281:11002–11010. [PubMed]
29. Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol. 2006;18:207–213. [PubMed]
30. Vang T, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nature Genet. 2005;37:1317–1319. [PubMed]
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...